EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interleukin-6 Gene Promoter Region Polymorphism in Patients with Dilated Cardiomyopathy: A Prospective Observational Study

Shiv Purari, Dhirendra Kumar, Sanjay Kumar, Sujit Kumar

Indian Journal of Pharmaceutical and Biological Research · 28.04.2026 · 14 (02) · 59-62

DOI: 10.30750/ijpbr.14.2.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Pharmaceutical and Biological Research, online erschienen am 28.04.2026. Verfasst von Shiv Purari und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dilated cardiomyopathy (DCM) is characterized by enlargement of the ventricular chambers with reduced myocardial contractility, leading to impaired cardiac performance. Its pathogenesis is multifactorial, involving a complex interplay between genetic susceptibility and inflammatory mechanisms. Interleukin-6 (IL-6), a pro-inflammatory cytokine, plays a key role in myocardial remodeling, and polymorphisms in its promoter region may influence disease susceptibility and severity.

Objective

To examine the relationship between IL-6 promoter gene polymorphism and clinical outcomes among patients with DCM.

Methods

This study was conducted at a tertiary care center inPawapuri, over 10 months (April 2025–January 2026). A total of 110 patients diagnosed with DCM were included. IL-6 promoter polymorphism (−174 G/C) was analyzed using PCR-based techniques. Clinical parameters and outcomes were recorded and statistically analyzed.

Results

The GG genotype was most prevalent (52.7%), followed by GC (34.5%) and CC (12.8%). Patients with the CC genotype showed significantly reduced left ventricular ejection fraction (LVEF) and higher NYHA class. The CC genotype was associated with increased hospitalization and mortality.

Conclusion

IL-6 promoter polymorphism is significantly associated with disease severity and outcomes in DCM patients, suggesting its potential role as a prognostic biomarker.

Zitieren

APA

Purari, S., Kumar, D., Kumar, S., & Kumar, S. (2026). Interleukin-6 Gene Promoter Region Polymorphism in Patients with Dilated Cardiomyopathy: A Prospective Observational Study. Indian Journal of Pharmaceutical and Biological Research, 14(02), 59-62. https://doi.org/10.30750/ijpbr.14.2.12

Vancouver

Purari S, Kumar D, Kumar S, Kumar S. Interleukin-6 Gene Promoter Region Polymorphism in Patients with Dilated Cardiomyopathy: A Prospective Observational Study. Indian Journal of Pharmaceutical and Biological Research. 2026;14(02):59-62. doi:10.30750/ijpbr.14.2.12

BibTeX
@article{Purari2026,
  author = {Purari, Shiv and Kumar, Dhirendra and Kumar, Sanjay and Kumar, Sujit},
  title = {Interleukin-6 Gene Promoter Region Polymorphism in Patients with Dilated Cardiomyopathy: A Prospective Observational Study},
  journal = {Indian Journal of Pharmaceutical and Biological Research},
  year = {2026},
  volume = {14},
  number = {02},
  pages = {59--62},
  doi = {10.30750/ijpbr.14.2.12}
}
Kostenlos starten →